Breaking News Instant updates and real-time market news.

CELG

Celgene

$85.85

0.25 (0.29%)

10:07
07/13/18
07/13
10:07
07/13/18
10:07

Juno's lisocabtagene maraleucel granted FDA orphan drug designation

Juno Therapeutics' lisocabtagene maraleucel was granted FDA orphan designation as a treatment of primary mediastinal large B-cell lymphoma, according to a post to the FDA website. Juno is a unit of Celgene. Reference Link

  • 26

    Jul

CELG Celgene
$85.85

0.25 (0.29%)

07/10/18
PIPR
07/10/18
NO CHANGE
PIPR
Neutral
Celgene raised prices on both Revlimid and Pomalyst by 5%, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that Wolters Kluwer Health reports that Celgene increased its prices for Revlimid and Pomalyst by 5%, effective yesterday. The analyst, who pointed out that this is the first increase since October 2017 for both drugs, said the price hikes should provide some tailwind to Celgene's second half results. He maintains his Neutral rating on Celgene shares.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
07/12/18
PIPR
07/12/18
NO CHANGE
Target $95
PIPR
Neutral
PTAB decision on Gilenya positive for Celgene, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond expects the market to react positively with respect to Celgene (CELG) shares, at least initially, following the Patent Trial and Appeal Board decision regarding ozanimod competitor Gilenya from Novartis (NVS). Yesterday, the PTAB issued a decision that upholds validity of Gilenya's dosing patent in response to inter partes review petitions from multiple generic filers, Raymond tells investors in a research note. While this decision will likely be appealed, it opens up the possibility for Gilenya intellectual property runway out to 2027, when the dosing patent expire, the analyst adds. Raymond believes that not having a generic S1P class at launch for ozanimod is positive for Celgene. However, without the removal of first dose monitoring, ozanimod is not likely to be differentiated enough to make a difference, the analyst says, citing physician feedback. He keeps a Neutral rating on Celgene with a $95 price target. The stock in early trading is up 2% to $84.92.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$225.18

-3.03 (-1.33%)

13:35
10/18/18
10/18
13:35
10/18/18
13:35
Periodicals
Goldman looks to 'weed out' women in class-action lawsuit, NY Post says »

Goldman Sachs says it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

TTWO

Take-Two

$125.92

-6.08 (-4.61%)

13:35
10/18/18
10/18
13:35
10/18/18
13:35
Options
TakeTwo Interactive Software put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

13:32
10/18/18
10/18
13:32
10/18/18
13:32
Hot Stocks
Breaking Hot Stocks news story  »

Mercantil Bank Holding…

PPG

PPG

$98.22

0.07 (0.07%)

13:28
10/18/18
10/18
13:28
10/18/18
13:28
Periodicals
PPG sees currency lowering Q4 sales by $50M-$60M vs. last year, Bloomberg says »

PPG, on its quarterly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

13:28
10/18/18
10/18
13:28
10/18/18
13:28
Hot Stocks
Breaking Hot Stocks news story  »

Bio Rad Laboratories…

URI

United Rentals

$123.97

-15.07 (-10.84%)

13:26
10/18/18
10/18
13:26
10/18/18
13:26
Recommendations
United Rentals analyst commentary  »

United Rentals price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

13:25
10/18/18
10/18
13:25
10/18/18
13:25
General news
Treasury Option Update: put spread positioning »

Treasury Option Update:…

ETE

Energy Transfer Equity

$17.05

(0.00%)

, ETP

Energy Transfer Partners

$21.83

0.03 (0.14%)

13:23
10/18/18
10/18
13:23
10/18/18
13:23
Hot Stocks
Energy Transfer Equity investors approve merger with Energy Transfer Partners »

Energy Transfer Equity,…

ETE

Energy Transfer Equity

$17.05

(0.00%)

ETP

Energy Transfer Partners

$21.83

0.03 (0.14%)

ET

Energy Transfer LP

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

13:23
10/18/18
10/18
13:23
10/18/18
13:23
Hot Stocks
Breaking Hot Stocks news story  »

Bio Rad Laboratories…

NVS

Novartis

$85.96

0.62 (0.73%)

13:22
10/18/18
10/18
13:22
10/18/18
13:22
Periodicals
FDA rejects Novartis's effort to repurpose inflammation drug, Reuters reports »

The FDA has snubbed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

KEY

KeyCorp

$18.31

-0.44 (-2.35%)

13:20
10/18/18
10/18
13:20
10/18/18
13:20
Options
Heavy call activity in KeyCorp as shares fall on earnings »

Heavy call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 30

    Oct

  • 16

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
10/18/18
10/18
13:17
10/18/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
10/18/18
10/18
13:16
10/18/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$73.15

-5.1 (-6.52%)

13:15
10/18/18
10/18
13:15
10/18/18
13:15
Hot Stocks
Blizzard says 'multiple teams' working on different 'Diablo' projects »

In a blog post ahead of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
10/18/18
10/18
13:15
10/18/18
13:15
General news
Treasury's $5 B 30-year TIPS sale was soft »

Treasury's $5 B…

13:12
10/18/18
10/18
13:12
10/18/18
13:12
Hot Stocks
Breaking Hot Stocks news story  »

Mercantil Bank Holding…

ARRY

Array BioPharma

$15.68

0.62 (4.12%)

13:10
10/18/18
10/18
13:10
10/18/18
13:10
Options
Array Biopharma attracts call buyers as shares see relative strength »

Array Biopharma attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOWR

Tower International

$25.87

-0.1 (-0.39%)

13:09
10/18/18
10/18
13:09
10/18/18
13:09
Hot Stocks
Tower International raised quarterly dividend to 13c from 12c per share »

The board of Tower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

KO

Coca-Cola

$45.77

-0.09 (-0.20%)

13:06
10/18/18
10/18
13:06
10/18/18
13:06
Hot Stocks
Coca-Cola names group presidents for Asia Pacific and Europe »

The Coca-Cola Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 30

    Oct

  • 03

    Mar

DIS

Disney

$116.37

-0.72 (-0.61%)

, FOX

21st Century Fox

$45.47

0.03 (0.07%)

13:05
10/18/18
10/18
13:05
10/18/18
13:05
Hot Stocks
Disney says Emma Watts to become vice chairman of 20th Century Fox Film »

Disney (DIS) announced…

DIS

Disney

$116.37

-0.72 (-0.61%)

FOX

21st Century Fox

$45.47

0.03 (0.07%)

FOXA

21st Century Fox

$45.84

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 14

    Nov

  • 14

    Nov

13:05
10/18/18
10/18
13:05
10/18/18
13:05
General news
30-Yr TIPS Auction Bid/Cover data reported »

30-Yr TIPS Auction…

13:05
10/18/18
10/18
13:05
10/18/18
13:05
General news
30-Yr TIPS Auction Total Amount data reported »

30-Yr TIPS Auction Total…

TWLO

Twilio

$71.40

-2.68 (-3.62%)

, TMUS

T-Mobile

$69.18

0.05 (0.07%)

13:04
10/18/18
10/18
13:04
10/18/18
13:04
Hot Stocks
Twilio, T-Mobile partner to create new developer platform Twilio Narrowband »

Building on their…

TWLO

Twilio

$71.40

-2.68 (-3.62%)

TMUS

T-Mobile

$69.18

0.05 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 06

    Nov

  • 12

    Nov

LION

Fidelity Southern

$22.96

-0.35 (-1.50%)

13:03
10/18/18
10/18
13:03
10/18/18
13:03
Earnings
Fidelity Southern reports Q3 EPS 47c, consensus 37c »

Total assets decreased by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

CVS

CVS Health

$74.36

0.04 (0.05%)

, AET

Aetna

$201.35

0.07 (0.03%)

13:02
10/18/18
10/18
13:02
10/18/18
13:02
Hot Stocks
NY DFS' Vullo says CVS-Aetna deal presents potential risks »

New York Department of…

CVS

CVS Health

$74.36

0.04 (0.05%)

AET

Aetna

$201.35

0.07 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.